



Invitation to presentation of Acarix´s second quarter 2025 report

Acarix invites investors, analysts, and media representatives to join a recorded webcast presentation of the second quarter report for 2025, scheduled for August 21st, at 15:00 CET. The presentation will be led by CEO Aamir Mahmood and will be conducted in English. Questions can be submitted via email in advance to Christian.lindholm@acarix.com until August 19th, 10am CET.

The report will be released in the morning on August 21st. Additionally, a PDF version of the presentation will be available on the Acarix website at 13:00.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact

Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments

[Invitation to presentation of Acarix´s second quarter 2025 report](#)